Delivery of inhibitor of growth 4 (ING4) gene significantly inhibits proliferation and invasion and promotes apoptosis of human osteosarcoma cells

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Li, Mei ^a   Zhu, Ye ^b   Zhang, Hongbin ^a   Li, Lihua ^a   He, Peng ^a   Xia, Hong ^a   Zhang, Yu ^a   Mao, Chuanbin ^b  

^a GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

^b UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; GELATINASE A; GELATINASE B; HOMEODOMAIN PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ING4 PROTEIN, HUMAN; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; BIOSYNTHESIS; BONE NEOPLASMS; CELL CYCLE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; OSTEOSARCOMA; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION;

APOPTOSIS; BONE NEOPLASMS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NF-KAPPA B; OSTEOSARCOMA; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84923268545     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep07380     Document Type: Article

References (60)

1. Sergi, C. & Zwerschke, W. Osteogenic sarcoma (osteosarcoma) in the elderly: tumor delineation and predisposing conditions. Exp Gerontol 43, 1039-1043 (2008).
2. Picci, P. Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis 2, 6 (2007).
3. Heymann, D. & Redini, F. Targeted therapies for bone sarcomas. Bonekey Rep 2, 378 (2013).
4. Scotlandi, K., Picci, P. & Kovar, H. Targeted therapies in bone sarcomas. Curr Cancer Drug Targets 9, 843-853 (2009).
5. Yarber, J. L.&Agulnik, M. Targeted therapies in bone sarcomas: current approach and future directions. Expert Opin Investig Drugs 20, 973-979 (2011).
6. Gaspar, N. et al. Bone sarcomas: from biology to targeted therapies. Sarcoma 2012, 301975 (2012).
7. Huang, H. J. et al. Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science 242, 1563-1566 (1988).
8. Coles, A. H. & Jones, S. N. The ING gene family in the regulation of cell growth and tumorigenesis. J Cell Physiol 218, 45-57 (2009).
9. Gunduz, M., Gunduz, E., Rivera, R. S. & Nagatsuka, H. The inhibitor of growth (ING) gene family: potential role in cancer therapy. Curr Cancer Drug Targets 8, 275-284 (2008).
10. Guo, Y. et al. The ING4 binding with p53 and induced p53 acetylation were attenuated by human papillomavirus 16 E6. PLoS One 8, e71453 (2013).
11. Byron, S. A. et al. Negative regulation of NF-kappaB by the ING4 tumor suppressor in breast cancer. PLoS One 7, e46823 (2012).
12. Ozer, A., Wu, L. C. & Bruick, R. K. The candidate tumor suppressor ING4 represses activation of the hypoxia inducible factor (HIF). Proc Natl Acad Sci U S A 102, 7481-7486 (2005).
13. Wei, Q. et al. Effect of the tumor suppressor gene ING4 on the proliferation of MCF-7 human breast cancer cells. Oncol Lett 4, 438-442 (2012).
14. Li, S. et al. Tumor suppressor ING4 overexpression contributes to proliferation and invasion inhibition in gastric carcinoma by suppressing the NF-kappaB signaling pathway. Mol Biol Rep 40, 5723-5732 (2013).
15. Lou, C., Jiang, S., Guo, X. & Dong, X. S. ING4 is negatively correlated with microvessel density in colon cancer. Tumour Biol 33, 2357-2364 (2012).
16. Zhu, Y. et al. Enhanced tumor suppression by an ING4/IL-24 bicistronic adenovirus-mediated gene cotransfer in human non-small cell lung cancer cells. Cancer Gene Ther 18, 627-636 (2011).
17. Liu, Y. et al. Expression of tumor suppressor gene ING4 in ovarian carcinoma is correlated with microvessel density. J Cancer Res Clin Oncol 138, 647-655 (2012).
18. Li,X. H. et al. Downregulation and translocation of nuclear ING4 is correlated with tumorigenesis and progression of head and neck squamous cell carcinoma. Oral Oncol 47, 217-223 (2011).
19. Li, J., Martinka, M. & Li, G. Role of ING4 in human melanoma cell migration, invasion and patient survival. Carcinogenesis 29, 1373-1379 (2008).
20. Fang, F. et al. Decreased expression of inhibitor of growth 4 correlated with poor prognosis of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 18, 409-416 (2009).
21. Wang, Q. S. et al. Down-regulation of ING4 is associated with initiation and progression of lung cancer. Histopathology 57, 271-281 (2010).
22. Klironomos, G. et al. Loss of inhibitor of growth (ING-4) is implicated in the pathogenesis and progression of human astrocytomas. Brain Pathol 20, 490-497 (2010).
23. Shen, J. C. et al. Inhibitor of growth 4 suppresses cell spreading and cell migration by interacting with a novel binding partner, liprin alpha1. Cancer Res 67, 2552-2558 (2007).
24. Garkavtsev, I. et al. The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature 428, 328-332 (2004).
25. You, Q.,Wang, X. S., Fu, S. B. & Jin, X. M. Downregulated expression of inhibitor of growth 4 (ING4) in advanced colorectal cancers: a non-randomized experimental study. Pathol Oncol Res 17, 473-477 (2011).
26. Moreno, A. et al. ING4 regulates a secretory phenotype in primary fibroblasts with dual effects on cell proliferation and tumor growth. Oncogene 33, 1945-1953 (2014).
27. MacLachlan, T. K., Sang, N. & Giordano, A. Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. Crit Rev Eukaryot Gene Expr 5, 127-156 (1995).
28. Malik, S., Saha, R.&Seth, P. Involvement of Extracellular Signal-Regulated Kinase (ERK1/2)-p53-p21 Axis in Mediating Neural Stem/Progenitor Cell Cycle Arrest in Co-Morbid HIV-Drug Abuse Exposure. JNeuroimmune Pharmacol 9, 340-353 (2014).
29. Tane, S. et al. CDK inhibitors, p21(Cip1) and p27(Kip1), participate in cell cycle exit of mammalian cardiomyocytes. Biochem Biophys Res Commun 443, 1105-1109 (2014).
30. Yoon, M. K., Mitrea, D. M., Ou, L. & Kriwacki, R. W. Cell cycle regulation by the intrinsically disordered proteins p21 and p27. Biochem Soc Trans 40, 981-988 (2012).
31. Vermeulen, K., Van Bockstaele, D. R. & Berneman, Z.N. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 36, 131-149 (2003).
32. Massague, J. G1 cell-cycle control and cancer. Nature 432, 298-306 (2004).
33. Shiseki, M. et al. p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity. Cancer Res 63, 2373-2378 (2003).
34. Zhang, X. et al. Nuclear localization signal of ING4 plays a key role in its binding to p53. Biochem Biophys Res Commun 331, 1032-1038 (2005).
35. Gartel, A. L. & Tyner, A. L. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 1, 639-649 (2002).
36. Karczmarek-Borowska, B. et al. Estimation of prognostic value of Bcl-xL gene expression in non-small cell lung cancer. Lung Cancer 51, 61-69 (2006).
37. Hwang, J.-H. et al. Apoptosis and bcl-2 expression as predictors of survival in radiation-treated non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 50, 13-18 (2001).
38. Cheng, E. H. et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell 8, 705-711 (2001).
39. Tang, Y. et al. Prognostic significance of KAI1/CD82 in human melanoma and its role in cell migration and invasion through the regulation of ING4. Carcinogenesis 35, 86-95 (2014).
40. Cottam, D. W. et al. Gelatinolytic metalloproteinase secretion patterns in ocular melanoma. Invest Ophthalmol Vis Sci 33, 1923-1927 (1992).
41. Jiang, M. C., Liao, C. F. & Lee, P. H. Aspirin inhibits matrix metalloproteinase-2 activity, increases E-cadherin production, and inhibits in vitro invasion of tumor cells. Biochem Biophys Res Commun 282, 671-677 (2001).
42. Raho, G. et al. Detection of novel mRNA splice variants of human ING4 tumor suppressor gene. Oncogene 26, 5247-5257 (2007).
43. Campos, E. I., Chin, M. Y., Kuo, W. H. & Li, G. Biological functions of the ING family tumor suppressors. Cell Mol Life Sci 61, 2597-2613 (2004).
44. Soliman, M. A. & Riabowol, K. After a decade of study-ING, a PHD for a versatile family of proteins. Trends Biochem Sci 32, 509-519 (2007).
45. Perkins, N. D. NF-kappaB: tumor promoter or suppressor? Trends Cell Biol 14, 64-69 (2004).
46. Moynagh, P. N. TLR signalling and activation of IRFs: revisiting old friends from the NF-kappaB pathway. Trends Immunol 26, 469-476 (2005).
47. Vincenti, M. P., Coon, C. I. & Brinckerhoff, C. E. Nuclear factor kappaB/p50 activates an element in the distal matrix metalloproteinase 1 promoter in interleukin-1beta-stimulated synovial fibroblasts. Arthritis Rheum 41, 1987-1994 (1998).
48. Han, Y. P. et al. TNF-alpha stimulates activation of pro-MMP2 in human skin through NF-(kappa)B mediated induction of MT1-MMP. J Cell Sci 114, 131-139 (2001).
49. Eberhardt, W. et al. Amplification of IL-1 beta-induced matrixmetalloproteinase- 9 expression by superoxide in rat glomerular mesangial cells is mediated by increased activities of NF-kappa B and activating protein-1 and involves activation of the mitogen-activated protein kinase pathways. J Immunol 165, 5788-5797 (2000).
50. Kawauchi, K. Araki, K. Tobiume, K. & Tanaka, N. p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat Cell Biol 10, 611-618 (2008).
51. Ryan, K. M., Ernst, M. K., Rice, N. R. & Vousden, K. H. Role of NF-kappaB in p53- mediated programmed cell death. Nature 404, 892-897 (2000).
52. Xu, M. et al. Adenovirus-mediated ING4 gene transfer in osteosarcoma suppresses tumor growth via induction of apoptosis and inhibition of tumor angiogenesis. Technol Cancer Res Treat, DOI: 10.7785/tcrt.2012.500424 (2014).
53. Misra, S. Human gene therapy: a brief overview of the genetic revolution. J Assoc Physicians India 61, 127-133 (2013).
54. Wang, Z. et al. Rapid and highly efficient transduction by double-stranded adenoassociated virus vectors in vitro and in vivo. Gene Ther 10, 2105-2111 (2003).
55. Rehman, K. K. et al. Efficient gene delivery to human and rodent islets with double-stranded (ds) AAV-based vectors. Gene Ther 12, 1313-1323 (2005).
56. Gandra, N.,Wang, D., Zhu, Y. & Mao, C. B. Virus-mimetic cytoplasma cleavable nanoclusters for enhanced gene delivery to mesenchymal stem cells. Angew Chem Int Ed 52, 11278-11281 (2013).
57. Abbineni, G. et al. Evolutionary selection of new breast cancer cell-targeting peptides and phages with the cell-targeting peptides fully displayed on the major coat and their effects on actin dynamics during cell internalization. Mol Pharm 7, 1629-1642 (2010).
58. Kalarical Janardhanan, S. et al. Architectonics of phage-liposome nanowebs as optimized photosensitizer vehicles for photodynamic cancer therapy. Mol Cancer Ther 9, 2524-2535 (2010).
59. Cao, B. et al. Stem cells loaded with nanoparticles as a drug carrier for in vivo breast cancer therapy. Adv Mater 26, 4627-4631 (2014).
60. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402-408 (2001).